Delayed O O O O
Cutaneous O O O O
Adverse O O O O
Reaction O O O O
of O O O O
the O O O O
AstraZeneca O O O O
COVID-19 O O O O
Vaccine O O O O
in O O O O
a O O O O
Breastfed O O O O
Female O O O O
Infant: O O O O
A O O O O
Coincidence O O O O
or O O O O
a O O O O
However, O O O O
as O O O O
a O O O O
novel O O O O
vaccine, O O O O
there O O O O
are O O O O
still O O O O
gaps O O O O
in O O O O
the O O O O
knowledge. O O O O
The O O O O
ChAdOx1 O O O O
nCoV-19 O O O O
vaccine O O O O
(Vaxzevria, O O O O
AstraZeneca, O O O O
Cambridge, O O O O
UK) O O O O
was O O O O
developed O O O O
at O O O O
Oxford O O O O
University O O O O
and O O O O
consists O O O O
of O O O O
a O O O O
replication-deficient O O O O
chimpanzee O O O O
adenoviral O O O O
vector O O O O
ChAdOx1, O O O O
which O O O O
carries O O O O
the O O O O
SARS-CoV-2 O O O O
structural O O O O
surface O O O O
glycoprotein O O O O
antigen O O O O
(spike O O O O
protein; O O O O
nCoV-19) O O O O
gene O O O O
that O O O O
can O O O O
enter O O O O
the O O O O
cells O O O O
yet O O O O
is O O O O
unable O O O O
to O O O O
replicate O O O O
[ O O O O
[4](#B4-vaccines-10-00602)]. O O O O
While O O O O
the O O O O
Pfizer-BioNTech O O O O
(Comirnaty, O O O O
BioNTech/Pfizer, O O O O
BNT162b2, O O O O
Mainz, O O O O
Germany) O O O O
and O O O O
vaccines O O O O
Cambridge, O O O O
MA, O O O O
USA) O O O O
are O O O O
messenger O O O O
ribonucleic O O O O
acid O O O O
(mRNA) O O O O
vaccines, O O O O
the O O O O
AstraZeneca/Oxford O O O O
vaccine O O O O
is O O O O
an O O O O
adenovirus O O O O
vector O O O O
vaccine O O O O
[ O O O O
[1](#B1-vaccines-10-00602), O O O O
[4](#B4-vaccines-10-00602)]; O O O O
it O O O O
contains O O O O
less O O O O
ingredients O O O O
when O O O O
compared O O O O
with O O O O
mRNA O O O O
vaccines, O O O O
as O O O O
shown O O O O
in O O O O
[Table O O O O
1](#vaccines-10-00602-t001), O O O O
and O O O O
requires O O O O
two O O O O
doses O O O O
given O O O O
four O O O O
weeks O O O O
apart O O O O
[ O O O O
[3](#B3-vaccines-10-00602)]. O O O O
[2](#B2-vaccines-10-00602)]. O O O O
All O O O O
vaccines O O O O
have O O O O
been O O O O
authorized O O O O
under O O O O
a O O O O
so-called O O O O
conditional O O O O
approval O O O O
scheme O O O O
by O O O O
the O O O O
European O O O O
Medicine O O O O
Agency O O O O
(EMA) O O O O
while O O O O
awaiting O O O O
further O O O O
evidence. O O O O
The O O O O
World O O O O
Health O O O O
Organization O O O O
(WHO) O O O O
advised O O O O
that O O O O
the O O O O
Pfizer-BioNTech O O O O
and O O O O
AstraZeneca O O O O
COVID-19 O O O O
vaccines O O O O
be O O O O
offered O O O O
to O O O O
breastfeeding O O O O
women, O O O O
and O O O O
the O O O O
discontinuation O O O O
of O O O O
breastfeeding O O O O
was O O O O
not O O O O
recommended O O O O
[ O O O O
[2](#B2-vaccines-10-00602)]. O O O O
As O O O O
the O O O O
ChAdOx1 O O O O
nCoV-19 O O O O
recombinant O O O O
vaccine O O O O
is O O O O
not O O O O
a O O O O
live-virus O O O O
vaccine, O O O O
it O O O O
is O O O O
biologically O O O O
and O O O O
clinically O O O O
unlikely O O O O
to O O O O
promote O O O O
a O O O O
risk O O O O
to O O O O
the O O O O
breastfeeding O O O O
child. O O O O
Despite O O O O
the O O O O
above O O O O
collected O O O O
data, O O O O
there O O O O
is O O O O
still O O O O
a O O O O
clear O O O O
gap O O O O
in O O O O
knowledge O O O O
regarding O O O O
the O O O O
possible O O O O
adverse O O O O
events O O O O
on O O O O
breastfed O O O O
infants O O O O
whose O O O O
mothers O O O O
have O O O O
been O O O O
vaccinated O O O O
with O O O O
the O O O O
COVID-19 O O O O
vaccines. O O O O
The O O O O
current O O O O
work O O O O
presents O O O O
a O O O O
short O O O O
report O O O O
of O O O O
a O O O O
33-year-old O O O O
breastfeeding O O O O
mother, O O O O
vaccinated O O O O
with O O O O
the O O O O
first O O O O
dose O O O O
of O O O O
the O O O O
AstraZeneca O O O O
vaccine, O O O O
who O O O O
did O O O O
not O O O O
reveal O O O O
clinical, O O O O
adverse O O O O
signs O O O O
or O O O O
symptoms O O O O
while O O O O
her O O O O
breastfed, O O O O
16-month-old O O O O
female O O O O
infant O O O O
had O O O O
cutaneous O O O O
adverse O O O O
reactions O O O O
(lower O O O O
extremities O O O O
and O O O O
face) O O O O
two O O O O
days O O O O
after O O O O
the O O O O
mother's O O O O
vaccine O O O O
administration. O O O O
This Reason 1 O O
episode Reason 1 O O
was Reason 1 O O
reported Reason 1 O O
immediately Reason 1 O O
to Reason 1 O O
the Reason 1 O O
pediatrician, Reason 1 O O
who Reason 1 O O
advised Reason 1 O O
the Reason 1 O O
parents Reason 1 O O
to Reason 1 O O
stay Reason 1 O O
alert Reason 1 O O
and Reason 1 O O
vigilant Reason 1 O O
due Reason 1 O O
to Reason 1 O O
the Reason 1 O O
mother's Reason 1 O O
administration Reason 1 O O
of Reason 1 O O
the Reason 1 O O
first Reason 1 O O
dose Reason 1 O O
of Reason 1 O O
the Reason 1 O O
AstraZeneca Reason 1 O O
vaccine. Reason 1 O O
After Reason 1 O O
12 Reason 1 O O
h, Reason 1 O O
the Reason 1 O O
leg Reason 1 O O
lesion Reason 1 O O
fully Reason 1 O O
recovered, Reason 1 O O
and Reason 1 O O
the Reason 1 O O
infant Reason 1 O O
was Reason 1 O O
apyretic. Reason 1 O O
On Reason 1 O O
the Reason 1 O O
third Reason 1 O O
day, Reason 1 O O
two Reason 1 O O
new Reason 1 O O
leg Reason 1 O O
urticarial Reason 1 O O
lesions Reason 1 O O
were Reason 1 O O
observed, Reason 1 O O
one Reason 1 O O
on Reason 1 O O
the Reason 1 O O
back Reason 1 O O
of Reason 1 O O
the Reason 1 O O
right Reason 1 O O
leg Reason 1 O O
and Reason 1 O O
the Reason 1 O O
other Reason 1 O O
on Reason 1 O O
the Reason 1 O O
anterior Reason 1 O O
region Reason 1 O O
of Reason 1 O O
the Reason 1 O O
left Reason 1 O O
leg. Reason 1 O O
After Reason 1 O O
10 Reason 1 O O
h, Reason 1 O O
both Reason 1 O O
spontaneously Reason 1 O O
disappeared. Reason 1 O O
On Reason 1 O O
the Reason 1 O O
fourth Reason 1 O O
day Reason 1 O O
after Reason 1 O O
the Reason 1 O O
vaccine, Reason 1 O O
a Reason 1 O O
cutaneous Reason 1 O O
rash Reason 1 O O
was Reason 1 O O
observed Reason 1 O O
on Reason 1 O O
the Reason 1 O O
infant's Reason 1 O O
face, Reason 1 O O
with Reason 1 O O
marked Reason 1 O O
uniformly Reason 1 O O
erythematous Reason 1 O O
tender Reason 1 O O
plaques Reason 1 O O
on Reason 1 O O
both Reason 1 O O
the Reason 1 O O
right Reason 1 O O
cheek Reason 1 O O
and Reason 1 O O
the Reason 1 O O
left Reason 1 O O
cheek. Reason 1 O O
After Reason 1 O O
11 Reason 1 O O
h, Reason 1 O O
both Reason 1 O O
extemporaneously Reason 1 O O
vanished. Reason 1 O O
On Reason 1 O O
the Reason 1 O O
fifth Reason 1 O O
day Reason 1 O O
after Reason 1 O O
the Reason 1 O O
mother's Reason 1 O O
first Reason 1 O O
vaccine Reason 1 O O
administration, Reason 1 O O
red-marked Reason 1 O O
targetoid Reason 1 O O
cutaneous Reason 1 O O
plaques Reason 1 O O
were Reason 1 O O
seen Reason 1 O O
on Reason 1 O O
the Reason 1 O O
left Reason 1 O O
buttock Reason 1 O O
and Reason 1 O O
the Reason 1 O O
left Reason 1 O O
leg. Reason 1 O O
These Reason 1 O O
disappeared Reason 1 O O
after Reason 1 O O
8 Reason 1 O O
h. Reason 1 O O
On Reason 1 O O
the Reason 1 O O
sixth Reason 1 O O
day Reason 1 O O
after Reason 1 O O
the Reason 1 O O
vaccine, Reason 1 O O
the Reason 1 O O
right Reason 1 O O
buttock Reason 1 O O
and Reason 1 O O
right Reason 1 O O
leg Reason 1 O O
showed Reason 1 O O
punctual Reason 1 O O
red Reason 1 O O
lesions Reason 1 O O
that Reason 1 O O
vanished Reason 1 O O
after Reason 1 O O
12 Reason 1 O O
h. Reason 1 O O
Due Reason 1 O O
to Reason 1 O O
the Reason 1 O O
constant Reason 1 O O
spontaneous Reason 1 O O
lesions' Reason 1 O O
improvement Reason 1 O O
and Reason 1 O O
after Reason 1 O O
a Reason 1 O O
telephone Reason 1 O O
discussion Reason 1 O O
with Reason 1 O O
the Reason 1 O O
pediatrician, Reason 1 O O
skin Reason 1 O O
cultures Reason 1 O O
were Reason 1 O O
not Reason 1 O O
advised. Reason 1 O O
The Reason 1 O O
infant Reason 1 O O
only Reason 1 O O
had Reason 1 O O
a Reason 1 O O
fever Reason 1 O O
once. Reason 1 O O
Diarrhea, Reason 1 O O
snot, Reason 1 O O
cough, Reason 1 O O
and Reason 1 O O
oral Reason 1 O O
lesions Reason 1 O O
were Reason 1 O O
not Reason 1 O O
observed. Reason 1 O O
For Reason 1 O O
caution, Reason 1 O O
the Reason 1 O O
infant Reason 1 O O
did Reason 1 O O
not Reason 1 O O
go Reason 1 O O
to Reason 1 O O
kindergarten Reason 1 O O
until Reason 1 O O
full Reason 1 O O
recovery. Reason 1 O O
Apparently, Reason 1 O O
the Reason 1 O O
cutaneous Reason 1 O O
lesions Reason 1 O O
did Reason 1 O O
not Reason 1 O O
cause Reason 1 O O
irritation Reason 1 O O
or Reason 1 O O
itching, Reason 1 O O
and Reason 1 O O
the Reason 1 O O
infant Reason 1 O O
always Reason 1 O O
had Reason 1 O O
an Reason 1 O O
appetite Reason 1 O O
and Reason 1 O O
ate Reason 1 O O
well. Reason 1 O O
The Reason 1 O O
infant Reason 1 O O
was Reason 1 O O
not Reason 1 O O
given Reason 1 O O
any Reason 1 O O
new Reason 1 O O
types Reason 1 O O
of Reason 1 O O
food, Reason 1 O O
and Reason 1 O O
there Reason 1 O O
were Reason 1 O O
no Reason 1 O O
changes Reason 1 O O
to Reason 1 O O
the Reason 1 O O
laundry Reason 1 O O
routines, Reason 1 O O
with Reason 1 O O
the Reason 1 O O
same Reason 1 O O
detergent Reason 1 O O
brands Reason 1 O O
used. Reason 1 O O
Moreover, Reason 1 O O
there Reason 1 O O
were Reason 1 O O
no Reason 1 O O
signs Reason 1 O O
or Reason 1 O O
symptoms Reason 1 O O
of Reason 1 O O
recent Reason 1 O O
or Reason 1 O O
chronic Reason 1 O O
infections, Reason 1 O O
no Reason 1 O O
associations Reason 1 O O
with Reason 1 O O
physical Reason 1 O O
stimuli, Reason 1 O O
and Reason 1 O O
no Reason 1 O O
contacts Reason 1 O O
with Reason 1 O O
inhaled Reason 1 O O
or Reason 1 O O
touched Reason 1 O O
substances. Reason 1 O O
Seven Reason 1 O O
days Reason 1 O O
after Reason 1 O O
the Reason 1 O O
vaccine Reason 1 O O
administration, Reason 1 O O
no Reason 1 O O
further Reason 1 O O
cutaneous Reason 1 O O
lesions Reason 1 O O
were Reason 1 O O
observed, Reason 1 O O
and Reason 1 O O
the Reason 1 O O
pediatrician Reason 1 O O
reported Reason 1 O O
the Reason 1 O O
situation Reason 1 O O
to Reason 1 O O
the Reason 1 O O
competent Reason 1 O O
authorities. Reason 1 O O
During O O O O
this O O O O
period, O O O O
breastfeeding O O O O
was O O O O
not O O O O
interrupted. O O O O
3. O O O O
Discussion O O O O
[5](#B5-vaccines-10-00602), O O O O
[6](#B6-vaccines-10-00602)]. O O O O
A O O O O
prospective O O O O
cohort O O O O
study O O O O
in O O O O
pregnant O O O O
and O O O O
lactating O O O O
women O O O O
from O O O O
the O O O O
US O O O O
found O O O O
that O O O O
vaccines O O O O
were O O O O
well O O O O
tolerated, O O O O
and O O O O
vaccine O O O O
reactions O O O O
in O O O O
these O O O O
groups O O O O
were O O O O
like O O O O
those O O O O
in O O O O
women O O O O
who O O O O
were O O O O
not O O O O
pregnant O O O O
or O O O O
breastfeeding O O O O
[ O O O O
[7](#B7-vaccines-10-00602)]. O O O O
Antibodies O O O O
generated O O O O
in O O O O
response O O O O
to O O O O
the O O O O
vaccine O O O O
should O O O O
protect O O O O
the O O O O
breastfeeding O O O O
women O O O O
and O O O O
the O O O O
breastfed O O O O
infants O O O O
[ O O O O
[7](#B7-vaccines-10-00602)]. O O O O
[1](#B1-vaccines-10-00602)]. O O O O
Only O O O O
two O O O O
case O O O O
reports O O O O
[ O O O O
[8](#B8-vaccines-10-00602), O O O O
[9](#B9-vaccines-10-00602)] O O O O
of O O O O
delayed O O O O
cutaneous O O O O
reactions O O O O
with O O O O
the O O O O
ChAdOx1 O O O O
nCoV-19 O O O O
vaccine O O O O
were O O O O
found, O O O O
analogous O O O O
to O O O O
the O O O O
ones O O O O
manifested O O O O
by O O O O
the O O O O
present O O O O
infant O O O O
lesions. O O O O
All O O O O
lesions O O O O
observed O O O O
in O O O O
the O O O O
breastfeeding O O O O
infant O O O O
were O O O O
similar O O O O
to O O O O
previous O O O O
descriptions O O O O
of O O O O
cutaneous O O O O
reactions O O O O
around O O O O
the O O O O
injection O O O O
site O O O O
in O O O O
people O O O O
who O O O O
had O O O O
been O O O O
vaccinated O O O O
with O O O O
other O O O O
COVID-19 O O O O
vaccines O O O O
[ O O O O
[10](#B10-vaccines-10-00602), O O O O
[11](#B11-vaccines-10-00602), O O O O
[12](#B12-vaccines-10-00602), O O O O
[13](#B13-vaccines-10-00602), O O O O
[14](#B14-vaccines-10-00602), O O O O
[15](#B15-vaccines-10-00602), O O O O
[16](#B16-vaccines-10-00602)]. O O O O
The O O O O
authors O O O O
state O O O O
that O O O O
this O O O O
is O O O O
a O O O O
remarkable O O O O
fact O O O O
that O O O O
deserves O O O O
attention O O O O
and O O O O
discussion O O O O
among O O O O
healthcare O O O O
professionals. O O O O
Furthermore, O O O O
those O O O O
several O O O O
descriptions O O O O
and O O O O
photographs O O O O
are O O O O
the O O O O
main O O O O
reason O O O O
as O O O O
well O O O O
as O O O O
triggering O O O O
point O O O O
for O O O O
the O O O O
presentation O O O O
of O O O O
this O O O O
case O O O O
report, O O O O
but O O O O
it O O O O
is O O O O
important O O O O
to O O O O
mention O O O O
that O O O O
until O O O O
the O O O O
present O O O O
moment, O O O O
this O O O O
is O O O O
the O O O O
only O O O O
clinical O O O O
case O O O O
report. O O O O
Within O O O O
this O O O O
report, O O O O
the O O O O
authors O O O O
propose O O O O
an O O O O
undeniable O O O O
visual O O O O
relationship O O O O
as O O O O
a O O O O
significant O O O O
point O O O O
between O O O O
the O O O O
vaccine O O O O
administration O O O O
and O O O O
the O O O O
infant's O O O O
delayed, O O O O
cutaneous, O O O O
adverse O O O O
reactions O O O O
as O O O O
there O O O O
is O O O O
no O O O O
other O O O O
apparent O O O O
cause O O O O
for O O O O
the O O O O
rash. O O O O
Due O O O O
to O O O O
the O O O O
cutaneous O O O O
manifestation's O O O O
clinical O O O O
history, O O O O
it O O O O
is O O O O
hypothesized O O O O
that O O O O
all O O O O
may O O O O
correspond O O O O
to O O O O
the O O O O
following: O O O O
(i) O O O O
a O O O O
delayed, O O O O
cutaneous, O O O O
adverse O O O O
reaction O O O O
to O O O O
mother's O O O O
first-dose O O O O
vaccine O O O O
(mainly O O O O
to O O O O
the O O O O
inactive O O O O
components); O O O O
(ii) O O O O
a O O O O
coincidental O O O O
event O O O O
(caused O O O O
by O O O O
viral O O O O
infections, O O O O
e.g., O O O O
parvovirus, O O O O
or O O O O
other O O O O
unidentified O O O O
allergens); O O O O
(iii) O O O O
an O O O O
infant O O O O
response O O O O
to O O O O
the O O O O
mother's O O O O
inflammatory O O O O
reaction O O O O
to O O O O
the O O O O
vaccine; O O O O
or O O O O
(iv) O O O O
a O O O O
common O O O O
immune O O O O
response O O O O
directed O O O O
against O O O O
the O O O O
spike O O O O
RNA O O O O
or O O O O
proteins O O O O
inducing O O O O
virus-associated O O O O
skin O O O O
lesions. O O O O
Since O O O O
the O O O O
infant O O O O
did O O O O
not O O O O
develop O O O O
humoral O O O O
immunity, O O O O
it O O O O
decreases O O O O
the O O O O
likelihood O O O O
that O O O O
the O O O O
cutaneous O O O O
reactions O O O O
were O O O O
mediated O O O O
by O O O O
the O O O O
active O O O O
vaccine O O O O
contents. O O O O
Moreover, O O O O
since O O O O
the O O O O
infant O O O O
did O O O O
not O O O O
present O O O O
a O O O O
cutaneous O O O O
reaction O O O O
with O O O O
previous O O O O
vaccines O O O O
containing O O O O
polysorbate O O O O
(e.g., O O O O
Prevenar O O O O
13®) O O O O
or O O O O
other O O O O
prior O O O O
medications, O O O O
authors O O O O
excluded O O O O
the O O O O
polysorbate O O O O
allergy, O O O O
considering O O O O
that O O O O
polysorbate O O O O
80 O O O O
(PS80), O O O O
the O O O O
AstraZeneca O O O O
vaccine's O O O O
main O O O O
component, O O O O
was O O O O
potentially O O O O
allergenic O O O O
or O O O O
immunogenic O O O O
[ O O O O
[17](#B17-vaccines-10-00602), O O O O
[18](#B18-vaccines-10-00602), O O O O
[19](#B19-vaccines-10-00602)] O O O O
